Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00541359 · ClinicalTrials.gov registry record · Phase 1
Bortezomib and Topotecan Hydrochloride in Treating Patients With Advanced Solid Tumors
A Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
- 2
- Study locations
NCT00541359 is a Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific that has completed, run by City of Hope Medical Center. The registered enrollment target is 54 participants, below the 500-participant average among 83 other Unspecified Adult Solid Tumor, Protocol Specific trials with a reported enrollment target (89% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT00541359, a Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific, has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
- 2
- Study locations
Study Summary
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as topotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving bortezomib together with topotecan hydrochloride may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of topotecan hydrochloride when given together with bortezomib in treating patients with advanced solid tumors.
Conditions Studied
Interventions
- OTHER immunohistochemistry staining method
- OTHER pharmacological study
- DRUG bortezomib
- DRUG topotecan hydrochloride
Study Locations (2)
California
- City of Hope Medical Center - Duarte
- City of Hope Medical Group Inc - Pasadena
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2004-01 |
| Est. Completion | 2011-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00541359
The ClinicalTrials.gov registry entry for NCT00541359 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 500-participant average among 83 other Unspecified Adult Solid Tumor, Protocol Specific trials with a reported enrollment target (89% lower). The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Unspecified Adult Solid Tumor, Protocol Specific appearing as the primary indexed condition, and to 4 interventions - of which immunohistochemistry staining method is the first listed.
NCT00541359 reports 2 study locations spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00541359 about?
NCT00541359 is a clinical study titled "Bortezomib and Topotecan Hydrochloride in Treating Patients With Advanced Solid Tumors". RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as topotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells ...
What is the current status of trial NCT00541359?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2004-01. Estimated completion is 2011-06.
What conditions does trial NCT00541359 study?
This clinical trial studies the following conditions: Unspecified Adult Solid Tumor, Protocol Specific.
What interventions are being tested in trial NCT00541359?
The interventions under investigation include: immunohistochemistry staining method (OTHER), pharmacological study (OTHER), bortezomib (DRUG), topotecan hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00541359?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00541359 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Unspecified Adult Solid Tumor, Protocol Specific
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
RNR Inhibitor COH29 in Treating Patients With Solid Tumors That Are Refractory to Standard Therapy or For Which No Standard Therapy Exists
ACTIVE NOT RECRUITING · Phase 1
-
Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors
COMPLETED · Phase 1
-
Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma
COMPLETED · Phase 1
-
PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma
COMPLETED · Phase 1
-
BMS-599626 in Treating Patients With Metastatic Solid Tumors
COMPLETED · Phase 1
-
Indole-3-Carbinol in Preventing Cancer in Healthy Participants
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.